{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:17:11Z","timestamp":1790223431123,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072032"],"award-info":[{"award-number":["82072032"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To conduct a cost-effectiveness analysis of drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) and conventional transcatheter arterial chemoembolization (cTACE) for first-line treatment of hepatocellular carcinoma (HCC) from the perspective of the Chinese healthcare system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Based on the real-world clinical data of HCC patients receiving interventional therapy, a partitioned survival model was constructed for cost-effectiveness analysis. The model period is 1 month, and the research time limit is 10 years. The incremental cost-effectiveness ratio (ICER) is used as the evaluation index. One-way sensitivity analysis and probabilistic sensitivity analysis were used to analyze the uncertainty of parameters to test the stability of the model results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The ICER of the DEB-TACE group was 11,875.62 $\/QALYs, which was lower than the willingness to pay threshold (WTP) of 31,499.23 $\/QALYs. One-way sensitivity analysis suggested that the utility value of progression-free survival (PFS) in the DEB-TACE group had the greatest impact. Probabilistic sensitivity analysis showed that at the level of WTP of 31,499.23 $\/QALYs, DEB-TACE had a cost-effective probability of 92%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Under the current economic level in my country, DEB-TACE is more cost-effective than cTACE in the treatment of HCC patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.963058","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T07:26:57Z","timestamp":1666769217000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Guoliang","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuojun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/nu8030156","article-title":"Dietary natural products for prevention and treatment of liver cancer","volume":"8","author":"Zhou","year":"2016","journal-title":"Nutrients."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/jjco\/hyw134","article-title":"Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection","volume":"46","author":"Zhu","year":"2016","journal-title":"Jpn J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jhepr.2019.02.003","article-title":"Controversies in the management of hepatocellular carcinoma","volume":"1","author":"Forner","year":"2019","journal-title":"JHEP Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2147\/CMAR.S152707","article-title":"Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different barcelona clinic liver cancer stages","volume":"10","author":"Guo","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1053\/j.semdp.2016.12.011","article-title":"The diagnosis and treatment of hepatocellular carcinoma","volume":"34","author":"Hartke","year":"2017","journal-title":"Semin Diagn Pathol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nrclinonc.2016.214","article-title":"Liver cancer: Regorafenib\u2014A new RESORCE in HCC","volume":"14","author":"Killock","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00270-012-0394-0","article-title":"Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis","volume":"35","author":"Malagari","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"8165","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.2217\/fon-2018-0136","article-title":"DEB-TACE: a standard review","volume":"14","author":"Melchiorre","year":"2018","journal-title":"Future Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.dld.2016.03.031","article-title":"Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma","volume":"48","author":"Cucchetti","year":"2016","journal-title":"Dig Liver Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14737167.2021.1893167","article-title":"Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments","volume":"21","author":"Rui","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health."},{"key":"B16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/00042737-200406000-00003","article-title":"Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls","volume":"16","author":"Bambha","year":"2004","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/0272989X16686559","article-title":"An overview of R in health decision sciences","volume":"37","author":"Jalal","year":"2017","journal-title":"Med Decis Making."},{"key":"B18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making."},{"key":"B19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40273-013-0053-6","article-title":"Transferability of indirect cost of chronic disease: a systematic review and meta-analysis","volume":"31","author":"Zhao","year":"2013","journal-title":"Pharmacoeconomics."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.jval.2018.05.002","article-title":"Valuation of euroqol five-dimensional questionnaire, youth version (EQ-5D-Y) and euroqol five-dimensional questionnaire, three-level version (EQ-5D-3L) health states: The impact of wording and perspective","volume":"21","author":"Kreimeier","year":"2018","journal-title":"Value Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","article-title":"Estimating an EQ-5D-5L Value Set for China","volume":"20","author":"Luo","year":"2017","journal-title":"Value Health."},{"key":"B22","first-page":"74","article-title":"Exploration on the value of discount rate for evaluation of pharmacoeconomics in my country","volume":"38","author":"Xie","year":"2019","journal-title":"Chin J Health Econ."},{"key":"B23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.963058\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T07:27:01Z","timestamp":1666769221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.963058\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":23,"alternative-id":["10.3389\/fpubh.2022.963058"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.963058","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"article-number":"963058"}}